Postsurgical Ensartinib in ALK-Positive NSCLC - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Postsurgical Ensartinib in ALK-Positive NSCLC

Adjuvant ensartinib may represent a new therapeutic strategy in completely resected disease.

  • By

  • Kathryn Wighton

  • July 31, 2026

  • 5 min

Share

Original Source(s)

Postsurgical Ensartinib in ALK-Positive NSCLC

  • by Kathryn Wighton

  • July 31, 2026

Related Content

Immune checkpoint crosstalk: CTLA-4/CD80 engagement as a predictor of anti-PD-1/PD-L1 therapy outcome in NSCLC

Correction: DPCrossU-Net: a dual-branch parallel CNN–Transformer network for lung nodule segmentation

Stereotactic versus hippocampal avoidance whole-brain radiotherapy combined with immune checkpoint inhibitors for multiple brain metastases in non-small cell lung cancer: a multi-center retrospective study